Targeting p38 MAPK pathway for the treatment of Alzheimer's disease

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• p38 mitogen-activated protein kinase (MAPK) signaling is a known contributor to neuroinflammation in Alzheimer's disease (AD).
• Emerging research highlights p38 MAPK's involvement in other AD-related processes, including excitotoxicity, synaptic plasticity, and tau phosphorylation.
• Despite its multifaceted roles, a comprehensive understanding and in vivo validation of p38 MAPK's significance in AD pathology are still developing.

Purpose of the Study:

• To provide an updated review on the role of p38 MAPK in neurodegeneration, specifically focusing on Alzheimer's disease.
• To summarize recent literature and key earlier studies concerning p38 MAPK in AD pathophysiology.
• To highlight the potential of p38 MAPK inhibitors as a therapeutic strategy for AD dementia.

Main Methods:

• Literature review and synthesis of recent and seminal research papers.
• Analysis of studies investigating p38 MAPK signaling pathways in the context of Alzheimer's disease.
• Focus on summarizing evidence related to neuroinflammation, excitotoxicity, synaptic plasticity, and tau phosphorylation.

Main Results:

• p38 MAPK signaling is implicated in multiple facets of Alzheimer's disease pathology, not solely neuroinflammation.
• Evidence suggests p38 MAPK influences excitotoxicity, synaptic plasticity, and tau phosphorylation, key events in AD.
• While direct quantification of behavioral improvements and in vivo evaluations are ongoing, p38 MAPK inhibitors are emerging as a potential treatment avenue.

Conclusions:

• p38 MAPK plays a complex and significant role in Alzheimer's disease pathogenesis.
• Targeting p38 MAPK represents a promising therapeutic strategy for managing Alzheimer's disease dementia.
• Further research is warranted to fully elucidate the in vivo effects and clinical benefits of p38 MAPK inhibition in AD.